| Identification | Back Directory | [Name]
Erlotinib D6 HCl | [CAS]
1189953-78-3 | [Synonyms]
Erlotinib D6
OSI-774 D6 hydrochloride
CP-358774 D6 hydrochloride
NSC 718781 D6 hydrochloride
[2H6]-Erlotinib Hydrochloride
Erlotinib Hydrochloride Impurity G | [Molecular Formula]
C22H18ClD6N3O4 | [MDL Number]
MFCD09840535 | [MOL File]
1189953-78-3.mol | [Molecular Weight]
435.934 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: slightly, heated,Methanol: slightly soluble | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Erlotinib-d6 (hydrochloride) contains six deuterium atoms located on the methoxy group. It is intended for use as an internal standard for the quantification of erlotinib by GC- or LC-MS. Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma (HN5) tumor xenografts in mice with an ED50 value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F (IC50 = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib are used to treat certain forms of cancer, including non-small cell lung cancer. | [Uses]
Erlotinib D6 HCl is a Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, Antineoplastic.;Labeled Erlotinib, intended for use as an internal standard for the quantification of Erlotinib by GC- or LC-mass spectrometry.
| [storage]
Store at -20°C | [References]
[1] LUCA GIANNI Giacomo G. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.[J]. I supplementi di Tumori?: official journal of Societa italiana di cancerologia ... [et al.], 2002, 1 4: S60-1.
[2] J D MOYER. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.[J]. Cancer research, 1997, 57 21: 4838-4848.
[3] ROY S HERBST Paul A B. Targeting the epidermal growth factor receptor in non-small cell lung cancer.[J]. Clinical Cancer Research, 2003, 9 16 Pt 1: 5813-5824.
|
|
|